Xaira Therapeutics is an AI-native biotech building generative models for protein and antibody design to create medicines that were previously out of reach.
Xaira emerged as one of the most prominent AI-native biotechs, built around advances in generative protein design. The company develops foundation models that design therapeutic proteins and antibodies against targets selected for clinical impact, integrating design, experimental validation, and development under one roof. Its scientific lineage includes leading work on protein-structure and design models, and its scale of funding reflects conviction that generative biology can produce a new class of medicines. Rather than selling tools, Xaira builds internal programs where model-designed molecules advance through its own pipeline, partnering selectively where collaboration accelerates progress. The company represents a bet that the design-build-test cycle of biologics is now dominated by computation. Xaira’s integrated model means experimental results continuously retrain design systems, so each program makes the generative capability stronger — a compounding advantage over one-off computational design exercises. The company has assembled substantial resources and talent to pursue ambitious programs over long timelines, reflecting the patience that biologic drug development demands even when computation accelerates design.
Xaira is a therapeutics company rather than a software vendor; engagement happens through partnerships and collaborations structured around programs, with terms defined case by case.
Biopharma organizations seeking partnerships in generative protein design, and researchers who want to work where model development and therapeutic development are the same activity. It attracts scientists who believe the most powerful application of design models is building medicines with them directly.